Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).Georgina V. Long, Michele Del Vecchio, Vanna Chiarion‐Sileni et al.|Journal of Clinical Oncology|2023Cited by 13
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced <i>BRAF</i>-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).Caroline Robert, Alexander Christopher Jonathan Van Akkooi, Bastian Schilling et al.|Journal of Clinical Oncology|2024Cited by 8